Dashboard
1
With a growth in Net Profit of 63.35%, the company declared Outstanding results in Jun 25
- The company has declared positive results for the last 2 consecutive quarters
- INTEREST COVERAGE RATIO(Q) The company hardly has any interest cost
- OPERATING CASH FLOW(Y) Highest at CNY 204.42 MM
- ROCE(HY) Highest at 8.54%
2
With ROE of 5.81%, it has a very attractive valuation with a 1.67 Price to Book Value
3
Market Beating Performance
Stock DNA
Pharmaceuticals & Biotechnology
CNY 3,430 Million (Small Cap)
29.00
NA
1.00%
0.02
5.81%
1.67
Revenue and Profits:
Net Sales:
421 Million
(Quarterly Results - Jun 2025)
Net Profit:
73 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-10.81%
0%
-10.81%
6 Months
-14.56%
0%
-14.56%
1 Year
49.0%
0%
49.0%
2 Years
26.46%
0%
26.46%
3 Years
-12.9%
0%
-12.9%
4 Years
-30.84%
0%
-30.84%
5 Years
-39.99%
0%
-39.99%
HVSEN Biotechnology Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
24.37%
EBIT Growth (5y)
5.65%
EBIT to Interest (avg)
28.86
Debt to EBITDA (avg)
2.06
Net Debt to Equity (avg)
0.32
Sales to Capital Employed (avg)
0.44
Tax Ratio
4.26%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
6.28%
ROE (avg)
4.83%
Valuation key factors
Factor
Value
P/E Ratio
29
Industry P/E
Price to Book Value
1.67
EV to EBIT
24.70
EV to EBITDA
13.46
EV to Capital Employed
1.65
EV to Sales
2.20
PEG Ratio
0.02
Dividend Yield
1.00%
ROCE (Latest)
6.70%
ROE (Latest)
5.81%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
420.60
396.50
6.08%
Operating Profit (PBDIT) excl Other Income
105.80
74.50
42.01%
Interest
2.50
9.20
-72.83%
Exceptional Items
-1.20
8.70
-113.79%
Consolidate Net Profit
72.80
44.80
62.50%
Operating Profit Margin (Excl OI)
181.00%
113.00%
6.80%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 6.08% vs -2.00% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 62.50% vs 61.15% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
1,189.80
1,010.20
17.78%
Operating Profit (PBDIT) excl Other Income
130.50
126.70
3.00%
Interest
43.00
28.60
50.35%
Exceptional Items
-24.00
12.00
-300.00%
Consolidate Net Profit
-19.80
16.80
-217.86%
Operating Profit Margin (Excl OI)
14.50%
6.30%
0.82%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 17.78% vs -0.38% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -217.86% vs -68.12% in Dec 2023
About HVSEN Biotechnology Co., Ltd. 
HVSEN Biotechnology Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






